A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors

Misako Nagasaka,1,2 Nadine Abdallah,3 Marcus Crosby,4 Nithin Thummala,1 Dhaval Patel,1 Antoinette J Wozniak,5 Shirish Gadgeel,6 Judith Abrams,1 Ammar Sukari1 1Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA; 2Department of Advanced Medical Innovations, St....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/51cf1ef1664c4646a9b81f0da427771f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:51cf1ef1664c4646a9b81f0da427771f
record_format dspace
spelling oai:doaj.org-article:51cf1ef1664c4646a9b81f0da427771f2021-12-02T03:08:07ZA retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors1179-2728https://doaj.org/article/51cf1ef1664c4646a9b81f0da427771f2019-09-01T00:00:00Zhttps://www.dovepress.com/a-retrospective-study-evaluating-the-pretreatment-tumor-volume-ptv-in--peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Misako Nagasaka,1,2 Nadine Abdallah,3 Marcus Crosby,4 Nithin Thummala,1 Dhaval Patel,1 Antoinette J Wozniak,5 Shirish Gadgeel,6 Judith Abrams,1 Ammar Sukari1 1Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA; 2Department of Advanced Medical Innovations, St. Marianna University Graduate School of Medicine, Kawasaki, Japan; 3Department of Internal Medicine, Wayne State University, Detroit, MI, USA; 4Department of Radiation Oncology, Gundersen Health System, La Crosse, WI, USA; 5Department of Oncology, University of Pittsburgh, Pittsburgh, PA, USA; 6Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USACorrespondence: Ammar SukariDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI 48201, USATel +1 313 576 8753Fax +1 313 576 8699Email sukaria@karmanos.orgIntroduction of hypothesis: Little information is available regarding the imaging characteristics that assist in differentiating responders from non-responders. We hypothesized that patients with higher pretreatment tumor volume (PTV) would have lower response rates and shorter overall survival (OS).Methods: Data from patients who received at least one dose of program death-1 (PD-1) inhibitors before August 31, 2016 were captured from our institution’s pharmacy database. The primary objective was to determine the association of PTV with best response, evaluated utilizing RECIST v1.1 criteria. Secondary objectives were estimation of progression-free survival (PFS) and OS. PTV was measured using the Philips Intellispace Multi-Modality Tumor Tracking application.Results: 116 non-small cell lung cancer (NSCLC) patients were evaluated. 66% patients had adenocarcinoma, 28% had squamous cell carcinoma and 5% had poorly differentiated NSCLC. Median PTV was 53.7 cm3 (95% CI: 13.3–107.9). Only one individual had no metastases and the remainder had M1 disease; 38% M1a, 10% M1b, 51% M1c. Most (79%) were previously treated. There were no complete responses; among those followed for at least 6 weeks, 26% had a partial response, 39% stable disease and 34% PD; 4% had no recorded response. There were no strong associations of PTV with any of the demographic or clinical characteristics. There was no association between PTV and OS (HR 1.2, P=0.26) or PFS (HR 1.1, P=0.47). Liver metastasis was associated with shorter survival (HR=2.8, P=0.05).Conclusion: PTV in NSCLC did not prove to be a predictor of response to PD-1 inhibitors but having liver metastasis was associated with significantly shorter survival.Keywords: non-small cell lung cancer, tumor volume, tumor burden, checkpoint inhibitorsNagasaka MAbdallah NCrosby MThummala NPatel DWozniak AJGadgeel SAbrams JSukari ADove Medical Pressarticlenon-small cell lung cancertumor volumetumor burdencheckpoint inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 10, Pp 95-105 (2019)
institution DOAJ
collection DOAJ
language EN
topic non-small cell lung cancer
tumor volume
tumor burden
checkpoint inhibitors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle non-small cell lung cancer
tumor volume
tumor burden
checkpoint inhibitors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Nagasaka M
Abdallah N
Crosby M
Thummala N
Patel D
Wozniak AJ
Gadgeel S
Abrams J
Sukari A
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
description Misako Nagasaka,1,2 Nadine Abdallah,3 Marcus Crosby,4 Nithin Thummala,1 Dhaval Patel,1 Antoinette J Wozniak,5 Shirish Gadgeel,6 Judith Abrams,1 Ammar Sukari1 1Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA; 2Department of Advanced Medical Innovations, St. Marianna University Graduate School of Medicine, Kawasaki, Japan; 3Department of Internal Medicine, Wayne State University, Detroit, MI, USA; 4Department of Radiation Oncology, Gundersen Health System, La Crosse, WI, USA; 5Department of Oncology, University of Pittsburgh, Pittsburgh, PA, USA; 6Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USACorrespondence: Ammar SukariDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI 48201, USATel +1 313 576 8753Fax +1 313 576 8699Email sukaria@karmanos.orgIntroduction of hypothesis: Little information is available regarding the imaging characteristics that assist in differentiating responders from non-responders. We hypothesized that patients with higher pretreatment tumor volume (PTV) would have lower response rates and shorter overall survival (OS).Methods: Data from patients who received at least one dose of program death-1 (PD-1) inhibitors before August 31, 2016 were captured from our institution’s pharmacy database. The primary objective was to determine the association of PTV with best response, evaluated utilizing RECIST v1.1 criteria. Secondary objectives were estimation of progression-free survival (PFS) and OS. PTV was measured using the Philips Intellispace Multi-Modality Tumor Tracking application.Results: 116 non-small cell lung cancer (NSCLC) patients were evaluated. 66% patients had adenocarcinoma, 28% had squamous cell carcinoma and 5% had poorly differentiated NSCLC. Median PTV was 53.7 cm3 (95% CI: 13.3–107.9). Only one individual had no metastases and the remainder had M1 disease; 38% M1a, 10% M1b, 51% M1c. Most (79%) were previously treated. There were no complete responses; among those followed for at least 6 weeks, 26% had a partial response, 39% stable disease and 34% PD; 4% had no recorded response. There were no strong associations of PTV with any of the demographic or clinical characteristics. There was no association between PTV and OS (HR 1.2, P=0.26) or PFS (HR 1.1, P=0.47). Liver metastasis was associated with shorter survival (HR=2.8, P=0.05).Conclusion: PTV in NSCLC did not prove to be a predictor of response to PD-1 inhibitors but having liver metastasis was associated with significantly shorter survival.Keywords: non-small cell lung cancer, tumor volume, tumor burden, checkpoint inhibitors
format article
author Nagasaka M
Abdallah N
Crosby M
Thummala N
Patel D
Wozniak AJ
Gadgeel S
Abrams J
Sukari A
author_facet Nagasaka M
Abdallah N
Crosby M
Thummala N
Patel D
Wozniak AJ
Gadgeel S
Abrams J
Sukari A
author_sort Nagasaka M
title A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
title_short A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
title_full A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
title_fullStr A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
title_full_unstemmed A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
title_sort retrospective study evaluating the pretreatment tumor volume (ptv) in non-small cell lung cancer (nsclc) as a predictor of response to program death-1 (pd-1) inhibitors
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/51cf1ef1664c4646a9b81f0da427771f
work_keys_str_mv AT nagasakam aretrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT abdallahn aretrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT crosbym aretrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT thummalan aretrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT pateld aretrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT wozniakaj aretrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT gadgeels aretrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT abramsj aretrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT sukaria aretrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT nagasakam retrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT abdallahn retrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT crosbym retrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT thummalan retrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT pateld retrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT wozniakaj retrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT gadgeels retrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT abramsj retrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
AT sukaria retrospectivestudyevaluatingthepretreatmenttumorvolumeptvinnonsmallcelllungcancernsclcasapredictorofresponsetoprogramdeath1pd1inhibitors
_version_ 1718401916365438976